Therapeutics for Moderate and Severe Dengue

The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.

NCT Number	NCT07543458
Lead Sponsor	Oxford University Clinical Research Unit, Vietnam Collaborators: University of Oxford, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, Number 2 Children's Hospital, Ho Chi Minh City, Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal, National Academy of Medical Sciences/Bir Hospital, Kathmandu, Nepal, Siriraj Hospital, Prince of Songkla University in Southern Thailand, Thailand, Dhaka Medical College, Chittagong Medical College Hospital, Chittagong, Bangladesh, Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia, Hospital Universitario Erasmo Meoz, Cucuta, Colombia, Fundación Valle del Lili, Cali, Colombia, Hospital Regional de Loreto, Iquitos, Peru, Instituto de Infectologia Emílio Ribas, São Paulo, Brazil, Universitas Sumatera Utara, Medan, Indonesia, Airlangga University (UNAIR), Indonesia, University Malaya Medical Centre, Malaysia, Hospital Queen Elizabeth II, Malaysia, San Lazaro Hospital (SLH-NU), Manila, Philippines
Conditions	Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever
Enrollment	8,800 participants
Start Date	2026-10-01
Primary Completion	2030-07-31 (estimated)
Study Completion	2031-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-21